The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes

American Journal of Psychiatry

Volumn 160, Issue 8, 2003, Pages 1421-1427

  Arango, Celso ^a   Buchanan, R W ^a   Breier, A ^a   MacMahon, R ^a   Carpenter, W T ^a  

^a MPRC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AMBULATORY CARE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CAUDATE NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMISPHERIC DOMINANCE; HIPPOCAMPUS; HISTOLOGY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; AKATHISIA; ANXIETY; BRAIN SIZE; CLINICAL ARTICLE; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; GRAY MATTER; HOSTILITY; NEGATIVE SYNDROME; OUTPATIENT CARE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; SIDE EFFECT; WHITE MATTER;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CAUDATE NUCLEUS; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; FUNCTIONAL LATERALITY; HALOPERIDOL; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0042882523     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.8.1421     Document Type: Article

References (35)

1. Buchanan RW: Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579-591
2. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
3. Friedman L, Knutson L, Shurell M, Meltzer HY: Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 1991; 29:865-877
4. Honer WG, Smith GN, Lapointe JS, MacEwan GW, Kopala L, Altman S: Regional cortical anatomy and clozapine response in refractory schizophrenia. Neuropsychopharmacology 1995; 13:85-87
5. Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, Lieberman JA: Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry 1994; 55(suppl B):53-56
6. Lauriello J, Mathalon DH, Rosenbloom M, Sullivan EV, Faustman WO, Ringo DL, Lim KO, Pfefferbaum A: Association between regional brain volumes and clozapine response in schizophrenia. Biol Psychiatry 1998; 43:879-886
7. Molina Rodríguez V, Montz Andreé R, Pérez Castejón MJ, Capdevila García E, Carreras Delgado JL, Rubia Vila FJ: SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am J Psychiatry 1996; 153:1343-1346
8. Molina Rodríguez V, Montz Andreé R, Pérez Castejón MJ, Zamora ML, Alvaro PC, Carreras Delgado JL, Rubia Vila FJ: Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients: a 99mTc-HMPAO study. Psychiatry Res 1997; 76:51-61
9. Buchanan RW, Carpenter WT Jr: The neuroanatomies of schizophrenia. Schizophr Bull 1997; 23:367-372
10. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Tamminga C, Wood F: Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993; 50:825-831
11. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
12. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155:751-760
13. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
14. Andreasen NC: The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 7:49-58
15. Buchanan RW, Carpenter WT: Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994; 182:193-204
16. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
17. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F: Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 1992; 49:921-926
18. Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT Jr: Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 1993; 150:59-65
19. Loats H, Holcomb H: Image analysis, in Medical Radiology Innovations in Diagnostic Radiology. Edited by Anderson J. Berlin, Springer-Verlag, 1989, pp 23-45
20. Schad LR, Brix G, Zuna I, Harle W, Lorenz WJ, Semmler W: Multiexponential proton spin-spin relaxation in MR imaging of human brain tumors. J Comput Assist Tomogr 1989; 13:577-587
21. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J: Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49:959-965
22. Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS: The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001; 24:47-54
23. Scheepers FE, Gispen de Wied CC, Hulshoff Pol HE, Kahn RS: Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. Am J Psychiatry 2001; 158:644-646
24. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, Borenstein M: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001; 58:965-972
25. Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D (Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia): Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999; 156:88-93
26. Kane J, Honigfeld G, Singer J, Meltzer H (Clozaril Collaborative Study Group): Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
27. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
28. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
29. Rosenheck R, Charney D, Cramer J, Xu W, Thomas J (VA CSH 17 Study Group): A randomized, double-blind trial of the efficacy and cost-effectiveness of clozapine (abstract). Schizophr Res 1997; 24:188
30. Marder SR, Van Putten T, Mintz J, McKenzie J. Lebell M, Faltico G, May PRA: Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41:1025-1029
31. Van Putten T, May PR, Marder SR: Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41:1036-1039
32. Nyberg S, Nakashima Y, Nordstrom AL, Halldin C, Farde L: Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs: review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry Suppl 1996; 29:40-44
33. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
34. Rollema H, Lu Y, Schmidt AW, Zorn SH: Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997; 338:R3-R5
35. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY: 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76:1521-1531